/
NMTC
$3.34+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$29.1M
9M shares
52-week range
$3.08 – $6.96
7% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
1.61%
Moderate
Price (6 mo)
Loading chart…
Change$-37.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.9M | $178.1K | $171.2K | $2.0M | $3.5M | $12.1M |
| Cost of revenue | $21.7K | $27.6K | $70.6K | $275.9K | $242.0K | $1.5M | $2.4M | $4.0M |
| Gross profit | −$21.7K | −$27.6K | $1.9M | −$97.7K | −$70.8K | $456.5K | $1.1M | $8.1M |
| Gross margin | — | — | 96.3% | -54.9% | -41.4% | 23.4% | 31.3% | 67.3% |
| R&D | $951.1K | $1.5M | $2.1M | $3.9M | $4.9M | $6.9M | $5.1M | $5.0M |
| Operating income | −$3.2M | −$5.8M | −$4.9M | −$10.2M | −$10.0M | −$12.0M | −$11.9M | −$4.2M |
| EBITDA | −$4.1M | −$5.8M | −$4.9M | −$9.8M | −$9.9M | −$11.7M | −$11.8M | −$3.0M |
| Net income | −$6.8M | −$6.8M | −$13.6M | −$9.9M | −$10.0M | −$11.9M | −$12.3M | −$3.6M |
| Net margin | — | — | -708.0% | -5584.3% | -5842.0% | -607.4% | -356.7% | -29.8% |
| EPS (diluted) | -14.58 | -10.32 | -15.12 | -5.58 | -3.78 | -3.90 | -2.76 | -0.54 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-1.28 | $-1.39–$-1.15 | 2 |
| 2027 | $15M | $-1.45 | $-1.57–$-1.30 | 2 |
| 2028 | $22M | $-0.72 | $-2.77–$1.33 | 2 |
| 2029 | $29M | $0.35 | $0.31–$0.38 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
NeuroOne Medical Technologies Corporation Common Stock
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
www.n1mtc.com- Employees
- 18
- IPO / List date
- Nov 9, 2012
- HQ
- EDEN PRAIRIE, MN
Held by traders on TradeandTell
No one on the platform currently holds NMTC.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NMTC as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-16 | 1-for-6reverse |
| 2021-04-01 | 1-for-3reverse |
Recent trades on TradeandTell
No one on the platform has traded NMTC yet.
